Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial
No Thumbnail Available
Authors
M. Parellada
A. San José Cáceres
R. Delorme
A. Moscoso
C. Moreno
R. Calvo
R. Canal-Bedia
M.A. Franco MartÃn
T. Charman
A. Strydom
Check for full-text access
Issue Date
22/01/2026
Type
Journal article
Language
Keywords
Children and Young People
Alternative Title
Abstract
Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777394.
Description
Citation
Parellada, M. et al. (2026) ‘Efficacy, safety, and tolerability of arbaclofen in Autistic children and adolescents, the AIMS-2-TRIALS-CT1: a randomized, double-blind, placebo-controlled phase II trial’, eClinicalMedicine, 92, p. 103760. Available at: https://doi.org/10.1016/j.eclinm.2026.103760.
Publisher
License
Journal
EClinicalMedicine
Volume
92